|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
The differential regulation of pulmonary surfactant proteins (SPs) is demonstrated in a murine model of Aspergillus fumigatus (Af )-induced allergic airway inflammation and hyperresponsiveness. BALB/c mice were sensitized intraperitoneally and challenged intranasally with Af extract. Enzyme-linked immunosorbent assay analysis of serum immunoglobulin (Ig) levels in these mice showed markedly increased total IgE and Af-specific IgE and IgG1. This was associated with peribronchial/perivascular tissue inflammation, airway eosinophilia, and secretion of interleukin (IL)-4 and IL-5 into the bronchoalveolar lavage fluid (BALF). Functional analysis revealed that in comparison with nonsensitized mice, allergic sensitization and challenge resulted in significant increases in acetylcholine responsiveness. To analyze levels of SPs, the cell-free supernate of the BALF was further fractionated by high-speed (20,000 × g) centrifugation. After sensitization and challenges, the pellet (large-aggregate fraction) showed a selective downregulation of hydrophobic SPs SP-B and SP-C by 50%. This reduction was reflected by commensurate decreases in SP-B and SP-C messenger RNA (mRNA) expression of the lung tissue of these animals. In contrast, there was a 9-fold increase in SP-D protein levels in the 20,000 × g supernate without changes in SP-D mRNA. The increased levels of SP-D showed a significant positive correlation with serum IgE (r = 0.85, P < 0.001). Tissue mRNA and protein levels of SP-A in either the large- or the small-aggregate fractions were unaffected. Our data indicate that allergic airway inflammation induces selective inhibition of hydrophobic SP synthesis accompanied by marked increases in the lung collectin SP-D protein content of BALF. These changes may contribute significantly to the pathophysiology of Af-induced allergic airway hyperresponsiveness.
| |
Introduction |
|---|
|
|
|---|
The alveoli and distal airways are lined by pulmonary surfactant, a mixture of phospholipid and protein, that functions to reduce surface tension at the air-liquid interface
and to participate in protective mechanisms against inhaled toxic, infectious, or allergenic substances (1, 2). Impairment of the intricately regulated synthesis, release, and
reuptake of four unique surfactant proteins (SPs)
SP-A,
SP-B, SP-C, and SP-D
by type II pneumocytes results in
surfactant dysfunction (3) and is believed to play a major role in disorders of the lung parenchyma, such as respiratory distress syndrome (6). Although potentially significant, the role of SPs in inflammatory diseases that affect
the airways, such as asthma, remains unknown.
Allergen-induced asthmatic responses include activation of T cells leading to a T helper (Th) 2-type inflammation with high serum immunoglobulin (Ig) E, eosinophilia, reversible airway obstruction, and airway hyperresponsiveness (AHR) (7). Pulmonary surfactant changes in this process may be important for two reasons. First, the hydrophobic SPs SP-B and SP-C shown to prevent collapse of alveoli at low lung volumes (8, 9) have also been implicated in maintaining patency of narrow conducting airways (10, 11). Thus, dysfunction of SP-B and SP-C may contribute to the enhanced resistance of the asthmatic airways (12). Second, the hydrophilic SPs (lung collectins) SP-A and SP-D are part of the innate immune system, and as such, they have potent effects on its cellular components and a binding ability to complex antigens, including microorganisms (13) and allergens (14). Collectins, therefore, may play a significant role in development and modulation of allergic responses in the airways. Notably, SP-A and SP-D were shown to specifically bind particles of Aspergillus fumigatus (Af ), indicating a direct involvement of these molecules in the processing of Af antigens and in the resulting inflammation (15, 16).
| |
Materials and Methods |
|---|
|
|
|---|
Mice, Sensitization, and Intranasal Challenge with Af Extract
To study the role of SPs, a murine model of Af-induced allergic sensitization was characterized. Female BALB/c mice were housed under pathogen-free conditions. Experiments were performed between 8 and 12 wk of age. All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. Two groups of mice were compared: "Naive" mice received intranasal vehicle challenges only, with 21% glycerol in phosphate-buffered saline (PBS). "Sensitized" mice were injected intraperitoneally with 20 µg Af (Bayer Pharmaceuticals, Elkhart, IN) together with 20 mg alum (Imject Alum; Pierce, Rockford, IL) in 100 µl on Days 1 and 14, followed by intranasal challenge on Days 25, 26, and 27 with 25 µl of Af extract in PBS (12.5 mg in 21% glycerol, PBS). Intranasal treatment was carried out essentially as described previously (17). Briefly, sensitized and control mice were anesthetized by isoflurane inhalation, and 25 µl of Af extract or vehicle, respectively, was applied to the left naris. The studies were performed and all mice were killed 24 h after their last intranasal treatment, when the peaks of eosinophil infiltration and airway responses were assumed to occur. Naive mice that received intranasal glycerol treatment alone showed no difference from nonsensitized, nonexposed normal BALB/c mice in any of the study parameters that we investigated, including lung histology, bronchoalveolar lavage (BAL) fluid (BALF) cellular content, Ig and cytokine profile, and airway responses to acetylcholine (ACh) (not shown).
In Vivo Measurement of Airway Responsiveness to ACh
Airway function measurements were carried out as previously described (20), modified as follows: Mice were anesthetized, cannulated, and ventilated (140 breaths/min; 0.2 ml tidal volume) after administration of pancuronium bromide (1.0 mg/kg). Transduced alveolar pressure and airflow rate (DP45 and DP103; Validyne, Northridge, CA) was used to calculate lung resistance (RL) and dynamic compliance (Cdyn) by a computer (Buxco Electronics, Inc., Troy, NY). Baseline RL and Cdyn values were established and after administration of saline, ACh was given intravenously at concentrations ranging from 80 to 1,280 µg/kg in five increments.
BALF Analysis for Differential Cell Count and Cytokine and Surfactant Content
Lungs were lavaged with either a small volume (1 ml) of sterile PBS or a large volume (5 ml) of sterile saline, and total and differential cell counts were performed as described previously (20, 21). Cytokine levels were determined from cell-free supernate of the small-volume BAL by enzyme-linked immunosorbent assay (ELISA) using antibodies and recombinant cytokines from PharMingen (San Diego, CA). To remove cells the large-volume BALF samples were centrifuged at 400 × g for 10 min at 4°C. The cell-free supernate was separated into two fractions by a second centrifugation at 20,000 × g for 60 min at 4°C. The pellet contained the large-aggregate (LA) surfactant fraction and the supernate contained soluble proteins as well as the small-aggregate (SA) fraction. For consistency with previous work (22, 23) we termed the supernate the SA fraction.
Total protein and phospholipid contents of the LA and SA fractions were determined using standard methods. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of LA and SA surfactant samples was carried out using NuPAGE 10% Bis-Tris gels (Novex, San Diego, CA) according to instructions of the manufacturer.
Rabbit polyclonal antisera against SP-A, SP-B, and SP-D were obtained and Western blots were performed as previously described (22). Antimature SP-C antibody was obtained from Byk Goulden Pharmaceuticals (Constance, Germany). Each lane was loaded with 5 µg of total protein.
Serum ELISA for Igs
Serum samples were collected as described elsewhere (20, 21). Antibodies and recombinant IgE were purchased from PharMingen and antibody levels were determined according to instructions of the manufacturer. For Af-specific antibody levels, plates (Dynatech, Chantilly, VA) were coated with Af (50 µg/ml in PBS, pH 7.1) and incubated overnight at 4°C. Samples were diluted 1:5 for Af-specific IgE and IgG2a, and 1:25 for IgG1 and total IgE. Data were analyzed with the Microplate Manager software program for the PC version (Bio-Rad, Hercules, CA).
Lung Tissue Histology and Analysis of Messenger RNA Expression
After lavage, lungs were inflated and fixed in paraformaldehyde (4% wt/vol in sodium cacodylate, 0.1 M, pH 7.3) for histologic analysis. Paraffin sections prepared from the lungs of naive and sensitized mice were stained with hematoxylin and eosin (H&E) for evaluation of airway inflammation.
In a different set of mice, total RNA was isolated from lungs
after BAL (23). Specific messenger RNA (mRNA) content was determined by Northern blot analysis. Nitrocellulose blots loaded with 10 µg total RNA per lane were hybridized under high stringency with [
-32P]complementary DNA (cDNA) probes for rat
SP-A, SP-B (23), SP-C, and SP-D (22) prepared from purified
plasmid inserts by labeling with [
-32P]deoxycytidine triphosphate
(Ready-to-Go Kit; Pharmacia, Piscataway, NJ) to specific activities of 6 to 8 × 106 counts per min/µg DNA as previously described
(22, 23). The specific signals were normalized for loading by hybridization of each blot with a 32P end-labeled ([
-32P]adenosine
triphosphate) 28S ribosomal RNA oligonucleotide probe. Specific
mRNA bands were quantified by Phosphoimager (Bio-Rad).
Data Analysis
Data are expressed as means ± standard error of the mean (SEM). Student's t test assuming equal variances was performed to test differences between groups and correlation was investigated by regression analysis. P < 0.05 was considered significant. Data were analyzed with the Sigmastat standard statistical package (Jandel Scientific, San Rafael, CA).
| |
Results and Discussion |
|---|
|
|
|---|
Characterization of Af-Induced Acute Airway Inflammation and Hyperresponsiveness
Af is a major airborne fungus responsible for a number of allergic disorders, including allergic bronchopulmonary aspergillosis (ABPA) and IgE-mediated asthma. In contrast to ABPA, in asthma the particles of Af sensitize the airways without fungal colonization (24). Our study aimed to reproduce this poorly characterized disease process in an animal model and to investigate whether pulmonary surfactants play a role.
To determine whether intranasally instilled Af would elicit an eosinophilic inflammatory response, a hallmark of Af-induced asthma, H&E sections of the lung tissue and the cellular content of the BALF were analyzed. Figure 1A shows that Af induced a predominantly perivascular (right upper panel) and peribronchial (right lower panel) inflammatory infiltrate that contained mainly mononuclear cells and eosinophils (Figure 1B, upper panel), with the lung parenchyma and the alveolar spaces being relatively preserved. The columnar epithelium of the airways remained intact, indicating that our model of acute allergic responses does not induce denudation or other damage to the epithelium. This is somewhat different from previously published models of Af-induced allergic sensitization in which mice received repeated intranasal Af exposure over a period of 3 wk and demonstrated more pronounced inflammatory changes with epithelial damage (18, 19). The BALF of sensitized and challenged mice (Figure 1B, lower panel, and Figure 1C) showed significant eosinophilia (P < 0.001), with approximately 40% of all the recovered cells being eosinophils.
|
Because elevated serum IgE and IgG to Af is a diagnostic feature of allergic asthma induced by Af and may be partly responsible for pathologic changes of the human lung (24), we analyzed total serum IgE together with the Af-specific Ig profile (IgE, IgG1, and IgG2a). There was an order of magnitude increase in the total serum IgE content after sensitization and challenge with Af (P < 0.001; Figure 1D, left panel) in addition to significantly elevated Af-specific IgE levels (P < 0.05; Figure 1D, middle panel). There were also robust increases in Af-specific IgG1 (P < 0.001, sensitized versus naive; Figure 1D, right panel). Levels of Af-specific IgG2a were slightly but also significantly elevated (P < 0.05). Our data indicate that sensitization and challenge with Af resulted in a characteristic Th2-type (interleukin [IL]-4-mediated) antibody profile in which total IgE and Af-specific IgG1 predominated.
Airway function measurements of mice sensitized and exposed to Af showed significant increases in RL and decreases in Cdyn in response to ACh when compared with naive animals (analysis of variance P < 0.001). Regression analysis revealed a significant correlation between the numbers of eosinophils and the extent of RL given at an ACh dose of 320 µg/kg (r = 0.75; P < 0.05), confirming a common base for Af-induced allergic airway inflammation and AHR (Figure 2A, right panel).
|
Because IL-4 and IL-5 are central in the development of
a Th2-type immune response, particularly in IgE production and airway eosinophilia, we characterized the local release of these cytokines by analyzing the BALF. IL-5 levels
in sensitized mice increased significantly (132 ± 32 versus
24 ± 6 pg/ml in naives; P < 0.01) and showed a significant
correlation with the numbers of eosinophils recovered from
the BALF of Af-sensitized mice (r = 0.764; P < 0.01; Figure
2B, lower left panel). In addition, sensitization markedly enhanced IL-4 release (60 ± 11 versus 1 ± 0 pg/ml; P < 0.01).
IL-4 positively correlated with IL-5 (r = 0.883; P < 0.001)
and negatively correlated with interferon (IFN)-
(r =
0.669; P < 0.01), indicating that predominance of Th2-type cytokines may exert an inhibitory effect on local IFN-
after Af-induced allergic sensitization. Taken together, similar to our previously characterized ovalbumin-induced
models of allergic AHR (20, 21), intraperitoneal sensitization and intranasal challenges with Af induced a predominantly Th2-like inflammatory response manifested by increases in serum IgE, IgG1, and an IL-5-driven eosinophil
accumulation in the lungs with altered airway function.
Sensitization and Challenge with Af Inhibited Hydrophobic SP-B and SP-C and mRNA Expression
LA and SA surfactant fractions of the BALF are morphologically and functionally different (25). Tubular myelin, large multilamellar vesicles, and lamellar bodies are observed in the LA fraction that is also responsible for the biophysical properties of surfactant. SP-A, SP-B, and SP-C are found mainly in this fraction. The SA fractions contain only small unilamellar vesicles and show poor surface activity both in vitro and in vivo. Centrifugation of cell-free BALF at 20,000 × g for 60 min results in a supernatant that contains the majority of SP-D and, also, the SA fraction is isolated with this portion.
In human respiratory distress syndrome and in models of experimental lung injury, changes in total protein and phospholipid levels are prominent (1). To study whether allergic inflammation in our model altered lung protein and phospholipid content, we analyzed the LA and SA pools as well as the cellular fraction of BALF samples in sensitized and control mice. Protein levels in the SA fraction of BALF were significantly higher than in the LA of the cellular fractions. Allergic sensitization resulted in increased protein levels in the SA fraction, which, however, did not attain statistical significance in this study (Table 1). The phospholipid levels were markedly higher in the LA than in the SA fraction in both animal groups, as expected; however, we observed no significant differences between sensitized and naive mice (Table 1), indicating no significant damage of type II epithelial cell function during allergic inflammation in this model.
|
Western blot analysis (Figures 3A and 3B) of the LA aggregate fraction of sensitized mice demonstrated significant reduction of the SP-B and SP-C levels when compared with naive mice (P < 0.05). No detectable levels of either SP-B or SP-C were found in the SA fraction. In addition, Northern blot analysis and densitometric evaluation of the 2-kb SP-B and 0.9-kb SP-C bands revealed marked decreases in normalized mRNA content in mice sensitized and challenged with Af when compared with nonsensitized control mice (P < 0.05 and P < 0.005, respectively). Thus, the alterations in hydrophobic SP levels (SP-B and SP-C) induced by allergic airway inflammation were reflected in commensurate changes in mRNA expression (Figures 3C and 3D). Cell activation during inflammation, as well as an influx of inflammatory cells, may result in decreased specific mRNA through increasing the total RNA levels in the lung. Although we took extra precautions to avoid such bias by normalizing mRNA levels to the 28S RNA content in each sample and by quantifying the amount of total RNA extracted from each lung that showed no significant differences between naive and sensitized groups in this study, we cannot entirely exclude the possibility that a dilutional effect contributed to the reduction of SP-B and SP-C mRNA we observed. Nevertheless, the proportionate decreases we found in the SP-B and SP-C levels were not the result of any such dilution by total protein because in the LA fraction the protein levels were virtually identical between sensitized and naive mice (Table 1).
|
The mechanism and physiologic significance of reduction in SP-B and SP-C during asthmatic inflammation are
unknown and require further investigation. Although a series of studies appears to corroborate the hypothesis that
surfactant dysfunction may be an important factor in obstruction of the asthmatic airways (10, 26) a role for
dysregulation of hydrophobic SPs has not been raised. Previously proposed mechanisms involve infiltration of airways with plasma proteins resulting in altered surfactant
phospholipid composition (26) and inhibition of surface activity (10, 11). Our findings extend this hypothesis by demonstrating that the hydrophobic SPs responsible for maintenance of surfactant activity (SP-B and SP-C) were inhibited
during asthmatic inflammation at both the protein and mRNA
levels. Thus, we suggest that the regulatory pathways of SP
production are also affected after sensitization and challenge with the allergen. This mechanism is not unique for
allergic airway inflammation, inasmuch as inhibition of hydrophobic SPs were demonstrated in other inflammatory
diseases such as respiratory distress syndrome (27) and
Pneumocistis carinii pneumonia (22, 23) and are attributed
to the regulatory effects of proinflammatory cytokines, particularly of tumor necrosis factor-
(28, 29). The hydrophobic SPs may play an important role in maintaining surface
tension of the alveoli and presumably patency of the small conducting airways (10, 26). The beneficial effects of
exogenous surfactant therapy have been indicated in a
guinea-pig model (30) as well as in asthmatic patients (31).
Thus, surfactant replacement may provide a useful adjunctive therapy in asthma.
Af-Induced Allergic Inflammation Is Associated with Increased SP-D Protein Expression
SP-D is a member of a novel, growing family of proteins that are believed to play a role in non-antibody-mediated innate immune response (2, 4). This family consists of SP-A and SP-D in the lung as well as mannose binding protein in the blood. Termed collectins, for collagen-like lectin, the primary function of these proteins appears to be modulation of host defense and inflammation. Previously, we have published reports that SP-A and SP-D expression are altered in response to P. carinii-induced pulmonary inflammation, supporting the concept that these lung collectins may play an active role in the inflammatory process (22, 23). After sensitization and exposure to Af we analyzed BALF for SP-A and SP-D levels and found that lung collectins were detectable in both LA and SA fractions of naive and sensitized mice by Western blot analysis. In the SA fraction, expression of the 43-kD SP-D protein was markedly increased in sensitized mice (P < 0.001, Figures 4A and 4B) with levels of the 35-kD SP-A remaining unaffected. In the LA surfactant fraction, levels of SP-A and SP-D were maintained during allergic inflammation (111 ± 9 and 148 ± 28% of control level, n = 10, respectively).
|
The mechanism of SP-D upregulation by type II cells in allergic inflammation is unclear. In contrast to SP-B and SP-C mRNA expression, levels of the 0.9-kb SP-A and 1.2-kb SP-D mRNA were not significantly affected by allergic changes (115 ± 19 and 143 ± 27% of control level, n = 5, respectively). These results suggest that increases in SP-D protein release into the airways may be due largely to altered post-translational processes, augmented release, and/ or reduced reuptake by epithelial cells (32) during allergic inflammation. Although it has been reported that regulators of SP expression include a variety of mediators and cytokines that also play important roles in the asthmatic inflammation (33), the exact mechanism of heightened SP-D protein production in our model awaits further clarification. Interestingly, in transgenic mice overexpressing IL-4, the cytokine central to the development of allergic changes and IgE synthesis, levels of SP-D protein were also disproportionately elevated when compared with SP-D mRNA (35). Further, analysis of the associations between SP-D and components of allergic airway inflammation revealed a significant positive correlation with serum total IgE (r = 0.85; P < 0.001), indicating a close relationship and a possible common regulatory pathway (Figure 4C). Taken together, these may suggest a regulatory function for IL-4 in SP-D production. The selective upregulation of SP-D during allergic AHR, coupled with its ability to bind allergens (14), implies a possible role for this lung collectin in development of allergic airway inflammation.
This report is the first detailed characterization of altered SP production in a model of allergic inflammation and AHR. Further studies are needed to clarify the role of SPs in the pathogenesis of asthma.
| |
Footnotes |
|---|
Address correspondence to: Angela Haczku, M.D., Ph.D., Pulmonary, Allergy and Critical Care Div., Dept. of Medicine, University of Pennsylvania Medical Center, 421 Curie Blvd., BRB II/III #840, Philadelphia, PA 19104-6061. E-mail: haczku{at}mail.med.upenn.edu
(Received in original form October 10, 2000 and in revised form February 8, 2001).
* These authors contributed equally to the manuscript.
Acknowledgments:
This work was supported by RO1 HL64520 & HL59867 (both
to M.F.B.). Angela Haczku is a Parker B. Francis Research Fellow in Pulmonary Medicine.
| |
References |
|---|
|
|
|---|
1. Griese, M.. 1999. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J. 13: 1455-1476 [Abstract].
2. Crouch, E., K. Hartshorn, and I. Ofek. 2000. Collectins and pulmonary innate immunity. Immunol. Rev. 173: 52-65 [Medline].
3. Rooney, S. A., S. L. Young, and C. R. Mendelson. 1994. Molecular and cellular processing of lung surfactant. FASEB J. 8: 957-967 [Abstract].
4.
Crouch, E. C..
1998.
Collectins and pulmonary host defense.
Am. J. Respir.
Cell Mol. Biol.
19:
177-201
5. Hawgood, S.. 1989. Pulmonary surfactant apoproteins: a review of protein and genomic structure. Am. J. Physiol. (Lung Cell. Mol. Physiol.) 263: L13-L22 .
6. Wiedmann, H. P.. 1996. Surfactant and acquired lung diseases. J. Lab. Clin. Med. 127: 239-241 [Medline].
7. Barnes, P. J. 1999. Therapeutic strategies for allergic diseases. Nature 402 (6760 Suppl):B31-B38.
8. Curstedt, T., H. Jornvall, B. Robertson, T. Bergman, and P. Berggren. 1987. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur. J. Biochem. 168: 255-262 [Medline].
9.
Beers, M. F., and
A. B. Fisher.
1992.
Surfactant protein C: a review of its
unique properties and metabolism.
Am. J. Physiol.
263:
L151-L160
10.
Hohlfeld, J. M.,
K. Ahlf,
G. Enhorning,
K. Balke,
V. J. Erpenbeck,
J. Petschallies,
H. G. Hoymann,
H. Fabel, and
N. Krug.
1999.
Dysfunction of
pulmonary surfactant in asthmatics after segmental allergen challenge.
Am. J. Respir. Crit. Care Med.
159:
1803-1809
11.
Jarjour, N. N., and
G. Enhorning.
1999.
Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant.
Am.
J. Respir. Crit. Care Med.
160:
336-341
12. Hohlfeld, J., H. Fabel, and H. Hamm. 1997. The role of pulmonary surfactant in obstructive airways disease. Eur. Respir. J. 10: 482-491 [Abstract].
13. Haagsman, H. P.. 1998. Interactions of surfactant protein A with pathogens. Biochim. Biophys. Acta 19: 264-277 .
14. Wang, J. Y., U. Kishore, B. L. Lim, P. Strong, and K. B. Reid. 1996. Interaction of human lung surfactant proteins A and D with mite (Dermatophagoides pteronyssinus) allergens. Clin. Exp. Immunol. 106: 367-373 [Medline].
15.
Allen, M. J.,
R. Harbeck,
B. Smith,
D. R. Voelker, and
R. J. Mason.
1999.
Binding of rat and human surfactant proteins A and D to Aspergillus fumigatus conidia.
Infect. Immun.
67:
4563-4569
16. Madan, T., P. Eggleton, U. Kishore, P. Strong, S. S. Aggrawal, P. U. Sarma, and K. B. Reid. 1997. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect. Immun. 65: 3171-3179 [Abstract].
17. Kurup, V., S. Mauze, H. Choi, B. W. P. Seymour, and R. L. Coffman. 1992. A murine model of allergic bronchopulmonary aspergillosis with elevated eosinophils and IgE. J. Immunol. 148: 3783-3788 [Abstract].
18.
Mehlhop, P. D.,
M. J. van de Rijn,
A. B. Goldberg,
J. P. Brewer,
V. P. Kurup,
T. R. Martin, and
H. C. Oettgen.
1997.
Allergen-induced bronchial
hyperreactivity and eosinophilic inflammation occur in the absence of IgE
in a mouse model of asthma.
Proc. Natl. Acad. Sci. USA
94:
1344-1349
19.
McLane, M. P.,
A. Haczku,
M. Van deRijn,
C. Weiss,
V. Ferrante,
D. MacDonald,
J.-C. Renauld,
N. C. Nicolaides,
K. J. Holroyd, and
R. C. Levitt.
1998.
Interleukin-9 promotes allergen-induced eosinophilic inflammation
and airway hyperresponsiveness in transgenic mice.
Am. J. Respir. Cell
Mol. Biol.
19:
713-720
20.
Haczku, A.,
K. Takeda,
I. Redai,
E. Hamelmann,
G. Cieslewicz,
A. Joetham,
J. Loader,
J. J. Lee,
C. G. Irvin, and
E. W. Gelfand.
1999.
Anti-CD86
(B7.2) treatment abolishes allergic airway hyperresponsiveness in mice.
Am. J. Respir. Crit. Care Med.
159:
1638-1643
21.
Haczku, A.,
K. Takeda,
E. Hamelmann,
J. Loader,
A. Joetham,
I. Redai,
C. G. Irvin,
J. J. Lee,
H. Kikutani,
D. Conrad, and
E. W. Gelfand.
2000.
CD23 exhibits negative regulatory effects on allergic sensitization and airway hyperresponsiveness.
Am. J. Respir. Crit. Care Med.
161:
952-960
22.
Atochina, E. N.,
M. F. Beers,
S. T. Scanlon,
A. M. Preston, and
J. M. Beck.
2000.
Pneumocystis carinii pneumonia induces selective alterations in
component expression and biophysical activity of pulmonary surfactant.
Am. J. Physiol. (Lung Cell. Mol. Physiol.)
278:
L599-L609
23. Beers, M. F., E. N. Atochina, A. M. Preston, and J. M. Beck. 1999. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J. Lab. Clin. Med. 133: 423-433 [Medline].
24. Cockrill, B. A., and C. A. Hales. 1999. Allergic bronchopulmonary aspergillosis. Annu. Rev. Med. 50: 303-316 [Medline].
25. Veldhuizen, R. A. W., K. Inchley, S. A. Hearn, J. F. Lewis, and F. Possmayer. 1993. Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem. J. 295: 141-147 .
26.
Heeley, E. L.,
J. M. Hohlfeld,
N. Krug, and
A. D. Postle.
2000.
Phospholipid
molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma.
Am. J. Physiol. (Lung Cell Mol. Physiol.)
278:
L305-L311
27.
Greene, K. E.,
J. R. Wright,
K. P. Steinberg,
J. T. Ruzinski,
E. Caldwell,
W. B. Wong,
W. Hull,
J. A. Whitsett,
T. Akino,
Y. Kuroki,
H. Nagae,
L. D. Hudson, and
T. R. Martin.
1999.
Serial changes in surfactant-associated
proteins in lung and serum before and after onset of ARDS.
Am. J. Respir.
Crit. Care Med.
160:
1843-1850
28.
Pryhuber, G. S.,
R. Khalak, and
Q. Zhao.
1998.
Regulation of surfactant
proteins A and B by TNF-
and phorbol ester independent of NF-
B.
Am.
J. Physiol.
274:
L289-L295
29.
Berhane, K.,
R. K. Margana, and
V. Boggaram.
2000.
Characterization of
rabbit SP-B promoter region responsive to downregulation by TNF-
.
Am. J. Physiol. (Lung. Cell. Mol. Physiol.)
279:
L806-L814
30. Liu, M., L. Wang, E. Li, and G. Enhorning. 1996. Pulmonary surfactant given prophylactically alleviates an asthma attack in guinea-pigs. Clin. Exp. Allergy 26: 270-275 [Medline].
31. Kurashima, K., H. Ogawa, T. Ohka, M. Fujimura, T. Matsuda, and T. Kobayashi. 1991. A pilot study of surfactant inhalation for the treatment of asthma attack. Jpn. J. Allergol. 40: 160-163 .
32. Wright, J. R., and L. G. Dobbs. 1991. Regulation of pulmonary surfactant secretion and clearance. Annu. Rev. Physiol. 53: 395-414 [Medline].
33. Bry, K., U. Lappalainen, and M. Hallman. 1996. Cytokines and production of surfactant components. Semin. Perinatol. 20: 194-205 [Medline].
34. Reed, J. A., and J. A. Whitsett. 1998. Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Proc. Assoc. Am. Physicians 110: 321-332 . [Medline]
35.
Ikegami, M.,
J. A. Whitsett,
Z. C. Chroneos,
G. F. Ross,
J. A. Reed,
C. J. Bachurski, and
A. H. Jobe.
2000.
IL-4 increases surfactant and regulates
metabolism in vivo.
Am. J. Physiol. (Lung Cell Mol. Physiol.)
278:
L75-L80
This article has been cited by other articles:
![]() |
R. Deb, F. Shakib, K. Reid, and H. Clark Major House Dust Mite Allergens Dermatophagoides pteronyssinus 1 and Dermatophagoides farinae 1 Degrade and Inactivate Lung Surfactant Proteins A and D J. Biol. Chem., December 21, 2007; 282(51): 36808 - 36819. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, C. MacLeod, B. Deng, L. Mason, M. Kasaian, S. Goldman, S. Wolf, C. Williams, and M. R. Bowman CAT-2 amplifies the agonist-evoked force of airway smooth muscle by enhancing spermine-mediated phosphatidylinositol-(4)-phosphate-5-kinase-{gamma} activity Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L883 - L891. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Haczku, Y. Cao, G. Vass, S. Kierstein, P. Nath, E. N. Atochina-Vasserman, S. T. Scanlon, L. Li, D. E. Griswold, K. F. Chung, et al. IL-4 and IL-13 Form a Negative Feedback Circuit with Surfactant Protein-D in the Allergic Airway Response J. Immunol., March 15, 2006; 176(6): 3557 - 3565. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Casey, J. Kaplan, E. N. Atochina-Vasserman, A. J. Gow, H. Kadire, Y. Tomer, J. H. Fisher, S. Hawgood, R. C. Savani, and M. F. Beers Alveolar Surfactant Protein D Content Modulates Bleomycin-induced Lung Injury Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 869 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Atochina, J. M. Beck, A. M. Preston, A. Haczku, Y. Tomer, S. T. Scanlon, T. Fusaro, J. Casey, S. Hawgood, A. J. Gow, et al. Enhanced Lung Injury and Delayed Clearance of Pneumocystis carinii in Surfactant Protein A-Deficient Mice: Attenuation of Cytokine Responses and Reactive Oxygen-Nitrogen Species Infect. Immun., October 1, 2004; 72(10): 6002 - 6011. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yang, A. Haczku, H. Chen, V. Martin, H. Galczenski, Y. Tomer, C. R. Van Beisen, J. F. Evans, R. A. Panettieri, and C. D. Funk Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4 Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L992 - L1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Krane and M. Griese Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis Eur. Respir. J., October 1, 2003; 22(4): 592 - 595. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takeda, N. Miyahara, Y.-H. Rha, C. Taube, E.-S. Yang, A. Joetham, T. Kodama, A. M. Balhorn, A. Dakhama, C. Duez, et al. Surfactant Protein D Regulates Airway Function and Allergic Inflammation through Modulation of Macrophage Function Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 783 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zhang, W. Pao, S. M. Umphress, S. B. Jakowlew, A. M. Meyer, L. D. Dwyer-Nield, L. D. Nielsen, K. Takeda, E. W. Gelfand, J. H. Fisher, et al. Serum Levels of Surfactant Protein D Are Increased in Mice with Lung Tumors Cancer Res., September 15, 2003; 63(18): 5889 - 5894. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Haczku, E. N. Atochina, Y. Tomer, Y. Cao, C. Campbell, S. T. Scanlon, S. J. Russo, G. Enhorning, and M. F. Beers The late asthmatic response is linked with increased surface tension and reduced surfactant protein B in mice Am J Physiol Lung Cell Mol Physiol, October 1, 2002; 283(4): L755 - L765. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |